Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Sharp & Dohme Ltd.

Division of Merck & Co. Inc.
www.msd-uk.com

Latest From Merck Sharp & Dohme Ltd.

EU Regulatory System Attacked Over Quality Of Approvals

If anyone can throw cold water on the claimed benefits of some of Europe's most recently approved medicines, it’s the international drug bulletin, Prescrire. In an assessment of 108 of the pharma industry’s latest offerings, it gives a cautious welcome to some but says that more than half bring nothing new and others could even be dangerous to patients.

Europe Drug Approval Standards

EU Firsts Beckon For Alnylam & Novo; Wins For A Raft Of Others

A plethora of new drugs moved closer to the EU market this week after the European Medicines Agency recommended that they should be approved.

Europe Approvals

MSD’s Ontruzant Gets Australian Reimbursement

Merck Sharp & Dohme’s Ontruzant has become the fourth trastuzumab biosimilar to be reimbursed in Australia, while Pfizer’s Trazimera is in line to be the fifth.

Australia Biosimilars

New Gene Therapies For Pediatric Diseases Win EMA PRIME Designations

Just two of six applications for entry into the European Medicines Agency’s priority medicines scheme for getting treatments for unmet medical needs to patients faster were successful last month.

Research and Development Strategies Europe
See All

Company Information

UsernamePublicRestriction

Register